Local Anesthetic Toxicity

Local Anesthetic Toxicity - Toxic Shock Waves

• Typical Sequence: CNS toxicity often precedes cardiovascular (CVS) signs.
• CNS "Wave":
  • Excitation: Early signs (metallic taste, tinnitus, circumoral numbness, dizziness, visual changes) → muscle twitching → tremors → generalized seizures.
  • Depression: Follows excitation: Drowsiness → unconsciousness → coma → respiratory arrest.
• CVS "Wave":
  • Initial (often missed): ↑HR, ↑BP (hypertension, tachycardia).
  • Progressive: ↓HR, ↓BP (hypotension, bradycardia), ventricular arrhythmias (VT/VF), ↓contractility.
  • Severe: Cardiovascular collapse, asystole.
  • ⚠️ Bupivacaine: High cardiotoxicity; difficult resuscitation.

⭐ Early CNS symptoms like metallic taste or tinnitus are crucial warning signs before severe CVS compromise occurs.

Local Anesthetic Toxicity - LAST's Red Flags

• Early CNS Manifestations (The "Canary in the Coal Mine"):
  • Perioral numbness, metallic taste, tinnitus
  • Lightheadedness, dizziness, anxiety, confusion
  • Visual disturbances (e.g., blurred vision)
  • Muscle twitching, tremors (especially face/extremities)
• Progressive CNS Toxicity:
  • Slurred speech
  • Generalized seizures (tonic-clonic)
  • Unconsciousness, coma
  • Respiratory depression leading to apnea
• ⚠️ Cardiovascular Manifestations (Often Delayed but More Sinister):
  • Initial (transient): Tachycardia, hypertension
  • Later: Bradycardia, hypotension
  • Arrhythmias: Ventricular tachycardia/fibrillation (VT/VF), QRS widening
  • Asystole, complete cardiovascular collapse

⭐ Bupivacaine is notorious for its high cardiotoxicity and difficult-to-treat arrhythmias in LAST, often resistant to standard resuscitation algorithms without lipid emulsion therapy.

Local Anesthetic Toxicity - Danger Zones

• Site-Specific Risk (Order of ↓ Systemic Absorption):
  • Intravenous (IV) > Tracheal > Intercostal > Caudal > Paracervical > Epidural > Brachial Plexus > Sciatic/Femoral > Subcutaneous.
  • 📌 Accidental IV injection = Highest immediate risk.
• Patient Factors ↑ Susceptibility:
  • Extremes of age (infants, elderly)
  • Pregnancy
  • Hepatic (amides) / Renal (esters) dysfunction
  • Cardiac disease (low EF, channelopathies)
  • Acidosis, hypoxia, hypercarbia (↓ seizure threshold, ↑ cardiotoxicity)
• Drug & Technique Factors:
  • Exceeding Max Safe Dose
  • Rapid / Intravascular injection
  • Potent LAs: Bupivacaine (high cardiotoxicity)
  • Absence of vasoconstrictor

⭐ Bupivacaine's cardiotoxicity is linked to its high lipid solubility and potent Na+ channel blockade; Levobupivacaine and Ropivacaine are safer alternatives.

oka

Local Anesthetic Toxicity - Rescue Mission

• Immediate Actions (S.O.S. Protocol):
  • Stop LA injection.
  • Oxygenate (100% O2), secure airway.
  • Seek help (LAST emergency). IV access.
• Seizure Control:
  • Benzodiazepines (e.g., Midazolam $0.05-0.1 \text{ mg/kg}$).
  • Avoid Propofol if CVS unstable.
• Lipid Emulsion Therapy (20%): 📌 "LIPID SINK"
  • Indication: Progressive CNS or any CVS toxicity.
  • Bolus: $1.5 \text{ mL/kg}$ IV over 1 min.
  • Infusion: $0.25 \text{ mL/kg/min}$.
  • Repeat bolus: 1-2x for persistent CVS collapse.
  • Max: $~10-12 \text{ mL/kg}$ (first 30 min).

  ⭐ The initial Intralipid 20% bolus dose is critical in severe LAST management.

• ACLS Modifications:
  • Epinephrine: Small doses ($<1 \text{ mcg/kg}$).
  • Amiodarone for VT/VF.
  • ⚠️ Avoid: Vasopressin, CCBs, Beta-blockers.
  • Prolonged CPR; consider CPB.
• Monitoring: At least 2-6 hrs post-event.

High‑Yield Points - ⚡ Biggest Takeaways

• CNS toxicity (e.g., circumoral numbness, tinnitus, metallic taste) typically precedes CVS toxicity.
• CNS progression: Excitation (seizures) followed by depression (coma, respiratory arrest).
• CVS toxicity manifests as hypotension, bradycardia, ventricular arrhythmias, and finally asystole.
• Bupivacaine is notoriously cardiotoxic ("ion trapping"); levobupivacaine and ropivacaine are safer alternatives.
• Treatment cornerstone: Stop LA injection, airway management (ABC), and 20% Lipid Emulsion Therapy.
• Key prevention: Aspirate before injecting, use ultrasound guidance, incremental dosing, and administer a test dose where appropriate.